Sep 26th 2012 - Edison Investment Research today published a report on SkyePharma (SKP.L, LSE:SKP, LON:SKP) entitled "A Flurry Of Activity...". In summary, the report says:
SkyePharma’s partner, Mundipharma, has now launched flutiform in the UK at a meaningful discount to the existing leading products. This suggests a different emphasis to flutiform’spositioning in Germany, where the discount was slight. In a busy week, theproposed restructuring of its convertible bonds was approved and Kyorin submitted flutiform for registration in Japan earlier than we expected. After adjusting for the restructuring of the bonds, our NPV model suggests the equity is worth 250p a share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »